ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstracts tagged "SLE and belimumab"

  • Abstract Number: 1086 • 2016 ACR/ARHP Annual Meeting

    Analysis of the Naive B Cell Repertoire in Belimumab Treated SLE Patients

    Weiqing Huang1, Cynthia Aranow2, Cosmin Dascalu1, Richard Furie3 and Anne Davidson4, 1Autoimmunity and Musculoskeletal Diseases, Feinstein Institute for Medical Research, Manhasset, NY, 2The Feinstein Institute for Medical Research, Manhasset, NY, 3Division of Rheumatology, North Shore LIJ Health System, Great Neck, NY, 4Autoimmunity and Musculoskeletal Diseases, Feinstein Inst for Med Rsch, Manhasset, NY

    Background/Purpose:  BAFF is a TNF-like cytokine that supports the survival and differentiation of B cells. The anti-BAFF antibody belimumab is the only new drug that…
  • Abstract Number: 1603 • 2013 ACR/ARHP Annual Meeting

    Sustained Reductions In Circulating B Cell Populations and Immunoglobulin G Levels With Long-Term Belimumab Treatment In Patients With Systemic Lupus Erythematosus

    Herbert Struemper1, William Freimuth2, Christi Kleoudis3, Thi-Sau Migone4, David Roth3 and William Stohl5, 1GlaxoSmithKline, Research Triangle Park, NC, 2Human Genome Sciences, Inc., Rockville, MD, 3GlaxoSmithKline, King of Prussia, PA, 4Igenica, Burlingame, CA, 5Division of Rheumatology, University of Southern California Keck School of Medicine, Los Angeles, CA

    Background/Purpose: Belimumab treatment in autoantibody-positive systemic lupus erythematosus (SLE) patients for up to 76 weeks results in sustained reduction in several circulating B cell subsets,…
  • Abstract Number: 1574 • 2013 ACR/ARHP Annual Meeting

    Favorable Clinical Response To Belimumab At Three Months

    Anca Askanase1, Arthi Reddy1, Jill P. Buyon2, Andrew G. Franks Jr.3, Richard A. Furie4, Diane L. Kamen5, Susan Manzi6, Michelle Petri7, Rosalind Ramsey-Goldman8, Chung-E Tseng9, Ronald F. van Vollenhoven10 and Daniel J. Wallace11, 1Rheumatology, New York University School of Medicine, New York, NY, 2Medicine, Division of Rheumatology, NYU School of Medicine, New York, NY, 3Dermatology & Medicine (Rheumatology), New York University, New York, NY, 4The Feinstein Institute for Medical Research and North Shore-Long Island Jewish Health System, Lake Success, NY, 5Department of Medicine, Division of Rheumatology, Medical University of South Carolina, Charleston, SC, 6Division of Rheumatology, University of Pittsburgh School of Medicine, Pittsburgh, PA, 7Johns Hopkins University School of Medicine, Baltimore, MD, 8Medicine/Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, IL, 9NYU School of Medicine, New York, NY, 10Clinical Trials Unit Department of Rheumatology, The Karolinska Institute, Stockholm, Sweden, 11Cedars-Sinai Medical Center, Los Angeles, CA

    Background/Purpose: Belimumab (Benlysta) is a human monoclonal antibody that inhibits soluble B-Lymphocyte Stimulator and improves SLE disease activity. This study was initiated to evaluate the…
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Convergence: Where Rheumatology Meets. All Virtual. November 5-9.

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2021 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
This site uses cookies: Find out more.